JAMES LEPAGE: Open Payments
NPI 1083146922 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,870 in 88 payments from 7 companies in 2025. Trend: 2023 $373 · 2024 $846 · 2025 $1,870
Food & beverage: $1,866Education: $4
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $600 |
| E.R. Squibb & Sons, L.L.C. | 23 | $371 |
| Teva Pharmaceuticals USA, Inc. | 14 | $284 |
| Otsuka America Pharmaceutical, Inc. | 14 | $254 |
| Alkermes, Inc. | 11 | $247 |
| Lundbeck LLC | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
Products named: INGREZZA, COBENFY, UZEDY, ARISTADA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, FANAPT, REXULTI.
Industry payments across AL — which companies pay providers there.
